Long‐Term Clinical Outcomes in Patients With Severe Tricuspid Regurgitation
Journal of the American Heart Association · 03.01.2023 · 12 (1)
DOI: 10.1161/jaha.122.025751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 03.01.2023. Verfasst von Naoki Nishiura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine Kobe City Medical Center General Hospital Kobe Japan. Hauptthemen laut MEDLINE: Tricuspid Valve Insufficiency, Atrial Fibrillation, Hypertension, Pulmonary, Heart Failure. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background The natural history and optimal interventional timing in patients with isolated severe tricuspid regurgitation (TR) have not been well studied. This study aimed to investigate long‐term clinical outcomes and risk factors associated with poor prognosis in patients with isolated severe TR. Methods and Results Consecutive transthoracic echocardiographic examinations in 2877 patients with isolated severe TR were retrospectively reviewed. Patients with significant left‐sided valve disease or repeated examinations were excluded. Primary outcome was defined as a composite of all‐cause death and hospitalization for heart failure. Among the 613 enrolled patients (mean age, 74±13 years; men, 38%), 141 died, and 62 were hospitalized for heart failure during the median follow‐up period of 26.5 (interquartile range, 6.0–57.9) months. The 5‐year event‐free rate was 60.1%. TR pressure gradient (adjusted hazard ratio [HR], 1.03 [95% CI, 1.01–1.04]), blood urea nitrogen (adjusted HR, 1.02 [95% CI, 1.01–1.04]), left atrial volume index (adjusted HR, 1.01 [95% CI, 1.002–1.02]), and serum albumin (adjusted HR, 0.56 [95% CI, 0.36–0.95]) were identified as independent predictors of adverse events. A risk model based on the 4 clinical factors that included pulmonary hypertension (TR pressure gradient >40 mm Hg), elevated blood urea nitrogen levels (>25 mg/dL), decreased albumin levels (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine Kobe City Medical Center General Hospital Kobe Japan.
- Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Osaka Japan.
- Department of Cardiothoracic Surgery Kobe City Medical Center General Hospital Kobe Japan.
ORCID-Profile: Naoki Nishiura, Takeshi Kitai, Taiji Okada, Norihisa Miyawaki, Kitae Kim, Ryosuke Murai, Natsuhiko Ehara, Atsushi Kobori, Makoto Kinoshita, Yutaka Furukawa
Zitieren
APA
Nishiura, N., Kitai, T., Okada, T., Sano, M., Miyawaki, N., Kim, K., Murai, R., Toyota, T., Sasaki, Y., Ehara, N., Kobori, A., Kinoshita, M., Koyama, T., & Furukawa, Y. (2023). Long‐Term Clinical Outcomes in Patients With Severe Tricuspid Regurgitation. Journal of the American Heart Association, 12(1). https://doi.org/10.1161/jaha.122.025751
Vancouver
Nishiura N, Kitai T, Okada T, Sano M, Miyawaki N, Kim K, et al. Long‐Term Clinical Outcomes in Patients With Severe Tricuspid Regurgitation. Journal of the American Heart Association. 2023;12(1). doi:10.1161/jaha.122.025751
BibTeX
@article{Nishiura2023,
author = {Nishiura, Naoki and Kitai, Takeshi and Okada, Taiji and Sano, Madoka and Miyawaki, Norihisa and Kim, Kitae and Murai, Ryosuke and Toyota, Toshiaki and Sasaki, Yasuhiro and Ehara, Natsuhiko and Kobori, Atsushi and Kinoshita, Makoto and Koyama, Tadaaki and Furukawa, Yutaka},
title = {Long‐Term Clinical Outcomes in Patients With Severe Tricuspid Regurgitation},
journal = {Journal of the American Heart Association},
year = {2023},
volume = {12},
number = {1},
doi = {10.1161/jaha.122.025751}
}
EUVIMED